Deutsche Bank’s downgrade of Novo Nordisk (NVO) to Sell after mixed second quarter earnings has refocused attention on the stock, with investors weighing prescription trends and obesity pipeline updates against recent share price weakness.

Novo Nordisk’s share price closed at US$47.19, with the 1 day share price return down 3.02% after the downgrade, adding to a year to date share price decline of 9.93% and a 1 year total shareholder return decline of 13.54%, which indicates weakening momentum despite periods of shorter term strength.

Spot shifting sentiment around Novo Nordisk and compare it with other large cap healthcare stocks that screen well for fundamentals using our curated list of solid balance sheet and fundamentals (51 results).

After Deutsche Bank’s downgrade and a year to date decline, Novo Nordisk now trades only slightly below the average analyst target, yet at a steep discount to some intrinsic value estimates. Where does fair value really sit in that spread?

Most Popular Narrative: 54.2% Undervalued

Novo Nordisk closed at $47.19, while the most followed valuation narrative from MCOInvestors puts fair value much higher, which creates a wide gap for investors to assess.

The GLP-1 market is growing at an unprecedented rate, with global sales projected to more than double from 2025 levels to reach $190 billion to $200 billion by 2035, with some forecasts projecting the market to exceed $250 billion by 2030-2034 due to the expansion into new therapeutic areas and rapid adoption of oral treatments.

However, if NVO receives expanded approval for adolescents in Q3 or Q4 of 2026, we believe capturing that market could drive the share price to $80-$85 by the end of 2026 based on revenue growth and margin expansion not yet factored in to the stock. Read the complete narrative.

Curious how MCOInvestors gets from today’s $47.19 to a fair value more than double that level. The story leans heavily on future GLP-1 uptake, richer margins and a premium earnings multiple that many investors usually associate with faster growing sectors.

According to MCOInvestors, the narrative rests on a blend of continued GLP-1 adoption, incremental margin expansion and an earnings multiple that implies the market could reward Novo Nordisk more in line with higher growth pharmaceutical peers if those assumptions play out.

Result: Fair Value of $102.97 (UNDERVALUED)

However, this upbeat Novo Nordisk narrative still faces risks if GLP-1 adoption slows, regulatory decisions disappoint, or potential acquisitions fail to create value.

Next Steps

If the mix of concerns and optimism around Novo Nordisk feels evenly balanced, do not wait passively. Review the key risks and potential upsides side by side with the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Novo Nordisk?

If Novo Nordisk has sharpened your focus on quality and price, use this moment to broaden your watchlist. Fresh ideas now can shape better outcomes later.

Do not leave your next move to chance. Put a clear process behind your stock hunting with a few focused screeners that surface opportunities in seconds.

• Target quality at a discount by scanning for companies that combine strong fundamentals with attractive pricing using our hand picked 51 high quality undervalued stocks.
• Prioritize resilience and support more predictable sleep by filtering for financially robust businesses through the 75 resilient stocks with low risk scores.
• Get ahead of the crowd by surfacing strong but less followed opportunities with the 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.